Search This Blog

Thursday, November 11, 2021

FTC approves ANI deal to buy Novitium, with conditions

 Specialty pharmacy company ANI Pharmaceuticals Inc has won U.S. antitrust approval to buy Novitium Pharma LLC on condition it divest rights or assets related to two generic medicines, the Federal Trade Commission said on Wednesday.

The companies, which announced their $210 million deal in March, agreed to sell ANI's development rights to generic sulfamethoxazole-trimethoprim oral suspension, a combination of antibiotics, and assets related to generic dexamethasone, used to treat inflammation and arthritis.

ANI already sells the antibiotic and is well-positioned to sell the anti-inflammatory while Novitium is a potential seller of both.

"Preserving the potential for entry ensures that the merged firm does not kill off ongoing product development efforts that could cause prices for its products to go down," said Holly Vedova, director of the FTC's Bureau of Competition, in a statement.

https://finance.yahoo.com/news/u-ftc-approves-ani-deal-210417890.html

Hims & Hers upped to Overweight from Neutral by Piper Sandler

 Target to $12 from $10

https://finviz.com/quote.ashx?t=hims&ty=c&ta=1&p=d

Adaptimmune: Positive Results in Pivotal Sarcoma Trial

 - SPEARHEAD-1 trial will meet its primary endpoint and data will be used to support BLA filing for afami-cel next year -

- The overall response rate (ORR) per Independent Review was 34% (36% in patients with synovial sarcoma and 25% for patients with MRCLS) and the disease control rate was 85% -

- As of the data cut-off, afami-cel has shown a favorable benefit:risk profile -

- Translational data confirm that afami-cel is active against MAGE-A4 expressing targets both in vitro and in vivo, and maintained high levels of persistence in the majority of patients followed for at least 6 months post-infusion -

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report updated clinical and translational data from its pivotal SPEARHEAD-1 trial with afamitresgene autoleucel (afami-cel, formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) at the Connective Tissue Oncology Society (CTOS) annual meeting.

“The positive results presented at CTOS further validate the potential of this therapy to address a great unmet medical need for patients with synovial sarcoma and MRCLS,” said Elliot Norry, Adaptimmune’s Chief Medical Officer. “We are confident that these data will support our BLA filing for afami-cel next year.”

“Afami-cel would provide a new treatment option for patients with synovial sarcoma, offering benefits that we have rarely seen with therapies currently available for this patient population,” said Dr. Brian A. Van Tine, Professor of Medicine and of Pediatrics at Washington University School of Medicine in St. Louis. “This is a game changer for patients with a high unmet medical need.”

Clinical data will be presented in an oral presentation by Dr. Brian Van Tine of the Washington University School of Medicine in St. Louis (Abstract #1080870) during the Immunotherapy & Immune Microenvironment Session starting at 10:00 a.m. EST on November 12th.

Merck KgaA 3Q Earnings Fell Despite Sales Growth; Confirms Raised Guidance

 Merck KgaA said Thursday that third-quarter earnings declined slightly on year, though sales increased, and confirmed a raised guidance for 2021 it had previously given.

The German pharmaceuticals-and-chemicals company posted earnings before interest, taxes, depreciation and amortization of 1.50 billion euros ($1.72 billion) for the quarter, down from EUR1.62 billion the year prior. After-tax profit also declined to EUR764 million from EUR806 million for the same period of 2020. Ebitda pre--a closely watched metric that excludes some one-time items--declined to EUR1.55 billion from EUR1.70 billion, which the company said was due to the impact of a provision reversal in the third quarter of 2020.

Merck confirmed that sales for the period grew to EUR4.97 billion from EUR4.45 billion in the third quarter of 2020, as it has previously communicated in an update.

It also confirmed the raised guidance it recently gave, saying that it expects organic growth of 13% to 15% for the full year, up from a previous forecast of 12% to 14% organic growth. As previously indicated, full-year sales are expected to be in the range of EUR19.3 billion to EUR19.85 billion, while Ebitda pre is expected to increase between 26% and 29% in teh full year, Merck said.

https://www.marketscreener.com/quote/stock/MERCK-KGAA-436395/news/Merck-KgaA-3Q-Earnings-Fell-Despite-Sales-Growth-Confirms-Raised-Guidance-36982092/

Wednesday, November 10, 2021

How gene mutation boosts cancer risk

 Researchers at the University of Virginia School of Medicine have discovered how a common gene mutation robs people of natural cancer protection.

Hao Jiang, PhD, of UVA Cancer Center, and his collaborators have revealed why a mutation in the UTX gene disrupts cells' ability to suppress tumors. The gene product, they found, forms tiny droplets in cells that help prevent tumor formation. But the mutation throws a wrench in that important process, leaving affected people vulnerable.

The new understanding of this vulnerability will help scientists and doctors as they seek better ways to battle and prevent cancer.

"How UTX inactivation causes human cancers remained elusive, as we did not know its key molecular activity that is critical for tumor suppression, posing a barrier to cancer therapies targeting UTX-related pathways," said Jiang, of UVA's Department of Biochemistry and Molecular Genetics. "Our work largely solved this mystery. Moreover, it suggests that disruption or alterations of these droplets can profoundly affect how our cells fight cancer. Forming proper droplets is likely to be a fundamental mechanism that maintains cellular health, and we are just beginning to understand."

Preventing Cancer Tumors

Jiang's work gives us a fascinating glimpse into an important way our bodies keep us safe from cancer. The UTX gene, he found, plays a vital role by directing the formation of "condensates" inside cells to prevent tumor formation. These little droplets condense from material in cells sort of like how water droplets condense on the outside of a cold glass. Once the droplets have formed, important biological processes can take place.

The droplets are important not just for suppressing tumors, Jiang and his team found, but for directing embryonic stem cells, generalized cells that can turn into highly specialized cells. For example, a stem cell might turn into a nerve cell or become bone.

For tumor suppression, the researchers found, the droplets control the activity of chromatin, the genetic material contained in our chromosomes. This ensures chromatin's "optimal activity," the scientists write in a new paper in the scientific journal Nature. The interaction, they note, "ensures efficient and correct chromatin modifications and interactions to orchestrate a proper tumour-suppressive transcriptional program."

Mutation of the UTX gene, however, robs cells of this important ability, putting people with the mutation at risk for cancer, the researchers conclude.

Another interesting finding in this work is that UTY, the Y-chromosome counterpart of UTX in men, forms condensates with more solid-like properties, making it less effective in suppressing cancer. This may contribute to the widely observed phenomenon that men are more likely to get cancer than women.

"We are very interested in how the condensate properties of UTX are regulated in cells and how other proteins may control cancer through forming droplets," Jiang said. "These studies will likely open up new approaches to cancer treatment by regulating these droplets."


Story Source:

Materials provided by University of Virginia Health SystemNote: Content may be edited for style and length.


Journal Reference:

  1. Bi Shi, Wei Li, Yansu Song, Zhenjia Wang, Rui Ju, Aleksandra Ulman, Jing Hu, Francesco Palomba, Yanfang Zhao, John Philip Le, William Jarrard, David Dimoff, Michelle A. Digman, Enrico Gratton, Chongzhi Zang, Hao Jiang. UTX condensation underlies its tumour-suppressive activityNature, 2021; 597 (7878): 726 DOI: 10.1038/s41586-021-03903-7

Mechanisms of drug side effects uncovered

 Researchers at Weill Cornell Medicine have discovered how drugs can affect various membrane-spanning proteins in addition to their intended target, potentially causing unwanted side effects. The results illuminate one of the central problems of drug discovery and point to new strategies for solving it.

Any class of drug can have side effects, but those that interact directly with cellular membranes have been especially problematic. "Those drugs tend to affect many membrane proteins, and we suspected that there's some kind of non-specific mechanism at work," said first author Dr. Radda Rusinova, assistant professor of research in physiology and biophysics at Weill Cornell Medicine. "We wanted to see whether it could be linked to the cell membrane."

In the study, published Nov. 9 in PNAS, Dr. Rusinova and her colleagues used sensitive assays that allowed them to compare how different drugs affected the activities of two channel proteins that span membranes: the gramicidin ion channel and a potassium channel called KcsA. Gramicidin was used to measure the magnitude of drugs' effect on the membrane while KcsA reflected effects these drugs could have on typical membrane proteins. They found that membrane-associated drugs can affect KcsA in at least three ways: by interacting directly with the proteins, by interfering with the proteins' structural connections to the membrane, or by causing broad changes in membrane characteristics such as thickness or elasticity.

Changes in membrane characteristics have well-known effects on the gramicidin ion channel, an antibiotic isolated from bacteria that has long been used as a standard tool for studying such changes. "Gramicidin is a probe essentially for changes in bilayer and membrane properties, and will report on the magnitude of the changes," said Dr. Rusinova.

"But we needed to go further to see how a more typical cell membrane protein would react," Dr. Rusinova said. KcsA belongs to a class of proteins -- potassium channels -- that drive many aspects of cell physiology in everything from bacteria to humans, making it a good comparative probe.

Results from the comparative assays revealed a more nuanced process than the straightforward model currently in use for explaining how membrane-binding drugs can affect membrane-spanning proteins.

"The more data that Dr. Rusinova got, the more it became apparent that this simple model did not actually cover the full spectrum of effects that we saw," said Dr. Olaf Andersen, professor of physiology and biophysics and senior author on the study.

"The investigators who are looking into molecules that can move into the cell membrane need to worry about at least three mechanisms for off-target effects," Dr. Rusinova said.

The news isn't all bad, though. In some cases, off-target effects at the cellular level cause no trouble to the organism, while in a few instances they can even be beneficial. To highlight the diversity of possible outcomes, Dr. Rusinova points to two of the drugs her team tested: amiodarone, a heart medication whose membrane-mediated effects actually boost its efficacy, and troglitazone, an anti-diabetic drug whose side effects included liver toxicity, ultimately forcing regulators to pull it from the market.

The investigators hope to extend their work by developing more predictive models for such off-target effects. "We would like to determine the structural characteristics of a membrane protein that would make it more or less sensitive to bilayer effects," Dr. Rusinova said.


Story Source:

Materials provided by Weill Cornell MedicineNote: Content may be edited for style and length.


Journal Reference:

  1. Radda Rusinova, Changhao He, Olaf S. Andersen. Mechanisms underlying drug-mediated regulation of membrane protein functionProceedings of the National Academy of Sciences, 2021; 118 (46): e2113229118 DOI: 10.1073/pnas.2113229118

Uber sued by Justice Department for overcharging disabled

 The US Justice Department (DoJ) is suing ride-hailing app Uber over allegations it has been overcharging disabled people.

The DoJ claims Uber's "wait time" fees are discriminating against disabled passengers who need more than two minutes to get into a car.

It says Uber needs to comply with the Americans with Disabilities Act (ADA).

But Uber said wait time fees were not intended to apply to disabled riders and that it had been refunding fees.

Kristen Clarke, assistance attorney general for the DoJ's civil rights division said the lawsuit aimed to send a "powerful message that Uber cannot penalise passengers with disabilities simply because they need more time to get into a car".

Uber and other companies that provide transportation services "must ensure equal access for all people, including those with disabilities," she added.


However, Uber said it disagreed that its policies were in violation of the the ADA.

A spokesman said the company had been in talks with the DoJ before the "surprising and disappointing" lawsuit.

Wait time fees were "never intended for riders who are ready at their designated pickup location but need more time to get into the car", he said.


Uber had a policy of refunding wait time fees for disabled riders whenever they alerted the firm that they had been charged, the spokesman said.

"After a recent change last week, now any rider who certifies they are disabled will have fees automatically waived," he added.

Uber's disability issues

Uber began charging passengers for driver waiting times in 2016.

The firm says riders are charged on average less than 60 cents, and that wheelchair-accessible trips or Uber Assist trips do not have any wait time fees by default.

It is not the first time that Uber has found itself in hot water over disability issues.

In April, it was ordered to pay a blind woman in San Francisco $1.1m after she was refused rides on 14 occasions. In the UK, Paralympic medallist Jack Hunter-Spivey said in September that Uber and other taxi drivers regularly drove off when they saw that he was a wheelchair user.

A 2020 study by the University of Tennessee found that it takes 28% more income for a disabled person in the US to achieve the same standard of living as a non-disabled person.


Maria Town, president and chief executive of the American Association of People with Disabilities (AAPD), who has cerebral palsy, told the BBC that disabled people often face a "disproportionate economic burden, often as a result of realities they cannot change nor control".

In addition to higher costs for health care, medical supplies and accessibility tools, the practice of applying extra fees for services, such as grocery delivery or rideshare wait times, adds an additional "tax" for disabled consumers, she said.

Ending the practice of charging wait-time fees for disabled riders would be a "step in the right direction toward economic equality and dignity", Ms Town added.

The AAPD said it had seen many cases where Uber drivers had driven away when they saw that the passenger was using a wheelchair, crutches, a walker or a service dog.

"The presence of disability alone sometimes is enough, it's a huge issue," Ms Town said, recalling an incident from 2017 concerning a man in Texas who had a genetic disorder that affected his appearance.

She also said that it was unfair of Uber to expect disabled people to use only its wheelchair-accessible services or Uber Assist.

"It's not fair on a number of fronts - there's a limited supply of these cars on the road, but also people with disabilities may not want assistance," she stressed.

Forcing someone to take an assist ride could cause "some tense driver-rider interactions that are completely unnecessary," Ms Town said.


https://www.bbc.com/news/business-59242866